Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies

Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, characterized by rapid proliferation, early metastatic dissemination, and poor long-term survival despite initial sensitivity to therapy. SCLC shares several biologic and therapeutic principles with hematologic malignancies, including lineage state dependence, adaptive resistance through non-genetic plasticity, and emerging susceptibility to antigen-directed immune therapies. Reframing SCLC through this lens provides a conceptual framework for understanding treatment failure and identifying new therapeutic strategies. A defining feature of SCLC is its dynamic transition between neuroendocrine (NE) and non-neuroendocrine (non-NE) states, driven by epigenetic and transcriptional reprogramming rather than new genetic alterations. These state transitions regulate antigen expression, immune visibility, and therapeutic vulnerability, enabling tumors to evade both cytotoxic and immune-based treatments. This plasticity parallels lineage switching and antigen escape observed in hematologic malignancies treated with targeted and immune therapies. Recent advances in antigen-directed therapy, particularly bispecific T cell engagers and antibody-drug conjugates targeting lineage-associated proteins such as DLL3, SEZ6, and TROP2, have demonstrated promising clinical activity. However, therapeutic efficacy is limited by antigen heterogeneity, evolving tumor states, and microenvironmental barriers including immune exclusion and T cell dysfunction. Epigenetic therapies targeting regulators such as EZH2 and LSD1 offer a strategy to reprogram tumor state, enhance antigen presentation, and sensitize tumors to immunotherapy. Beyond lineage biology, SCLC exhibits dependence on replication stress and DNA damage response pathways, though targeting these vulnerabilities alone has yielded modest clinical benefit. Emerging evidence highlights the role of metabolic and stress-response adaptations, including lactate-mediated immune suppression and integrated stress signaling, in sustaining tumor fitness and resistance. Circulating tumor DNA and epigenomic profiling provide noninvasive approaches to monitor tumor evolution, lineage state, and treatment response over time, offering potential for biomarker-guided therapeutic adaptation. Overall, durable clinical benefit in SCLC will likely require temporally sequenced, biomarker driven combination strategies that anticipate and constrain tumor plasticity. Integrating lineage-directed targeting, epigenetic modulation, immune engagement, and metabolic intervention may enable more effective and sustained disease control in this highly adaptive cancer.